EASD 2025: REDEFINE 2 trial unveils meaningful weight reduction with CagriSema
At the European Association for the Study of Diabetes (EASD) Annual Meeting 2025, findings were shown from the Phase IIIa …
Post
-
-
EASD 2025: Viperin signals a path to targeted beta‑cell preservation in T1D
At the 2025 European Association for the Study of Diabetes meeting in Vienna, University of Dundee researchers reported that Viperin …
-
Mabwell and Aditum launch Kalexo Bio for siRNA therapy development
China’s Mabwell Bioscience and US-based Aditum Bio have launched Kalexo Bio, a new company, to develop a new small interfering …
-
EASD 2025: Early UK screening for T1D shows real-world readiness
At the 2025 European Association for the Study of Diabetes (EASD) meeting in Vienna, investigators reported that the Early Surveillance …
-
EASD 2025: SAB-142 Phase I data demonstrates novel T1D immunotherapy
At the 2025 European Association for the Study of Diabetes (EASD) meeting in Vienna, SAB Biotherapeutics presented Phase 1 data …
-
Big pharma companies hit with FDA warning letters in drug ad clampdown
The US Food and Drug Administration (FDA) has followed up on its promise to clampdown on misleading and deceptive drug …
-
EASD 2025: Zimislecel infusion advances insulin independence in T1D
At the 2025 European Association for the Study of Diabetes (EASD) meeting in Vienna, investigators reported one-year outcomes from FORWARD, …
-
Solving global CDMO challenges: Indena and TCG GreenChem’s strategic-alliance
Contract development and manufacturing organisations (CDMOs) are facing mounting pressures to streamline production processes while adhering to increasingly stringent quality …
-
Eli Lilly picks Virginia for $5bn drug manufacturing plant
Eli Lilly has revealed the foremost plans from its new swathe of new drug manufacturing facilities it aims to build …
-
VarmX and CSL form alliance for blood coagulation treatment development
VarmX has established a partnership with CSL for the development of VMX-C001, designed to aid in restoring blood coagulation in …
-
GSK plans $30bn investment for R&D in US
GSK has announced an investment of $30bn in the US over the next five years for research and development (R&D) …
-
Reunion Neuroscience expands Series A to $133m after positive trial milestones
The success of Reunion Neuroscience’s lead psychedelic candidate in a postpartum depression (PPD) trial has provided a last minute boost …
-
European Society of Cardiology (ESC) Annual Meeting 2025
The European Society of Cardiology (ESC) Annual Meeting 2025, held from August 29 to September 1 in Madrid, Spain, showcased …
-
Novo Nordisk secures EMA approval for Rybelsus label update
Novo Nordisk has received the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) approval for the …
-
aTyr Pharma stock crashes on Phase III pulmonary sarcoidosis fail
aTyr Pharma shares plunged more than 80% after its Phase III trial in pulmonary sarcoidosis failed to meet its primary …
